TY - JOUR
T1 - Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes
AU - Phani, Nagaraja M.
AU - Vohra, Manik
AU - Kakar, Ananth
AU - Adhikari, Prabha
AU - Nagri, Shivashankara K.
AU - D'Souza, Sydney C.
AU - Umakanth, Shashikiran
AU - Satyamoorthy, Kapaettu
AU - Rai, Padmalatha S.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.
AB - Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.
UR - http://www.scopus.com/inward/record.url?scp=85049916591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049916591&partnerID=8YFLogxK
U2 - 10.2217/pgs-2018-0041
DO - 10.2217/pgs-2018-0041
M3 - Article
AN - SCOPUS:85049916591
SN - 1462-2416
VL - 19
SP - 905
EP - 911
JO - Pharmacogenomics
JF - Pharmacogenomics
IS - 11
ER -
